NEWS

Analysis of patent layout of telpopeptide in China

Release time:

2023-11-23 16:33

 

2023Year11Month8Day, Lilly's Tilpotide (Tirzepatide, the trade name isZepbound) beFDAOfficially approved for the treatment of obesity.Previously, in2023Year10Month15Day, Tilpotide just ended a four-yearIIIphase clinical study, and inNatureMedicineThe journal published its gratifying results. The results of the study show thatBMI ≥ 30kg/m²orBMI ≥ 27kg/m²Non-concomitant with at least one comorbid condition2type 2 diabetes adult patients, after intensive lifestyle intervention,72The primary endpoint of efficacy evaluation and treatment evaluation was met by weekly telpotide, and the average weight loss was achieved.21.1%; and84Week (72 12weeks of intensive lifestyle intervention), total mean weight loss of up26.6%(29.2kg), placebo group only3.8%(4.1kg）。And in terms of safety, the most commonly reported adverse events were gastrointestinal-related and were usually only mild to moderate in severity. And as early as last year5month,FDATilpotide has been approved for the treatment2Treatment of type 2 diabetes.

as a kindGIP/GLP-1Dual-target agonist, tilpotide in all aspects of the show than the previous.GLP-1The single-target star drug Smeglutide has greater potential, so it can be expected that in the future, Tilpotide is likely to occupy a significant portion of Smeglutide's market share. In this regard, Lilly has made a full patent layout in advance, the following is a brief analysis of the Chinese patent of Tilpotide.

Compound Patent for Tilpotide (Grant Announcement No.CN107207576B) The application date is2016Year01Year05Day, currently authorized, estimated2036Year01Year05The day expires, and there is a considerable life cycle. At the same time, Lilly also filed a division of the compound patent (open No.CN112608377A), is currently under substantive review. Tilpotide formulation patent (publication No.CN112312926A) provides an injection of telpotide, the application date is.2019Year06Month14It is also currently under substantive review. In addition, in2020Year01Month28On the same day, Lilly also applied for a patent for a new intermediate and preparation method of tiportide (CN113330024A), is also currently in the substantive review stage. With regard to patents for use, up to now, there are four published patent applications, which are in the order of application date:CN112469431A(2019Year07Month22day),CN112512633A(2019Year07Month22day),CN115279395A(2021Year01Month22day),CN116867505A(2022Year02Month02Day), is also currently under substantive review. However, all four patents describe the use.The way of "treatment of disease" is presented, which does not belong to the object of protection of China's patent law, especially the latter two articles. The claims only contain the treatment of disease. Unless there are other subjects that may be authorized in the specification, the probability of rejection is very high. The first two articles, in addition to the topic of treatment methods, also include the topic of composition or application of tilpotide, so they have certain authorization prospects. Therefore, based on the information currently known, it is speculated that the longest Chinese patent cycle for telpotide may be expected to extend2040Year or so.